TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06169137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Time-Restricted Eating
Description: Participants will be provided all meals to consume within a 6-hour timeframe (9:30-3:30p)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional dietary regimen (12-hr, 9:30a-9:30p)
Description: Participants will be provided all meals to consume within a 12-hour timeframe (9:30a-9:30p)
Study: NCT05901012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine
Description: DMT will be administered using a vaporizer device in a placebo-controlled, double-blind, randomized, monocentric clinical trial design.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DMT will be administered using a vaporizer device in a placebo-controlled, double-blind, randomized, monocentric clinical trial design.
Study: NCT05398952

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory investigations
Description: Laboratory investigations correlated with symptoms and imaging results

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory investigations
Description: Laboratory investigations correlated with symptoms and imaging results

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory investigations
Description: Laboratory investigations correlated with symptoms and imaging results

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory investigations
Description: Laboratory investigations correlated with symptoms and imaging results
Study: NCT06277271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette
Description: Participants will be supplied with an e-cigarette along with a 4-week supply of e-liquid. Participants will receive training on how to use the device and practice puffing with the e-cigarette during the research visit. They will be instructed to self-regulate administration according to their craving and withdrawal symptoms and to refrain from using other nicotine and tobacco products.
Study: NCT06228924

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TN-401
Description: TN-401 is a recombinant adeno-associated virus serotype 9 (AAV9) gene therapy containing Plakophilin-2 (PKP2) transgene. It is a single (one-time) intravenous dose.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TN-401
Description: TN-401 is a recombinant adeno-associated virus serotype 9 (AAV9) gene therapy containing Plakophilin-2 (PKP2) transgene. It is a single (one-time) intravenous dose.
Study: NCT06442098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMP SMART Literacy Summer Camp
Description: Multimodal approach to reading intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMP SMART Literacy Summer Camp
Description: Multimodal approach to reading intervention
Study: NCT05189327

Intervention type: OTHER
Intervention: No intervention
Description: Non-interventional study
Study: NCT05259150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health for Hearts United Planning for Health
Description: Participants (health leaders) receive trainings (three entitled Take Charge of Your Health, Eat Better, \& Move Around More) and plan for their health ministry and cardiovascular health program to congregants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health for Hearts United Planning for Health
Description: Participants (health leaders) receive trainings (three entitled Take Charge of Your Health, Eat Better, \& Move Around More) and plan for their health ministry and cardiovascular health program to congregants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health for Hearts United Preparing for Health
Description: Research participants (church congregants) receive cardiovascular health programming prepared by health leaders that includes the following best practices: Individual Goal Setting, Training, Culturally-tailored Materials, Monitoring Tool \& Recognition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health for Hearts United Preparing for Health
Description: Research participants (church congregants) receive cardiovascular health programming prepared by health leaders that includes the following best practices: Individual Goal Setting, Training, Culturally-tailored Materials, Monitoring Tool \& Recognition.
Study: NCT05097118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Versus Bupivacaine
Description: Drugs Ketamine versus Bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Versus Bupivacaine
Description: Drugs Ketamine versus Bupivacaine
Study: NCT05271838

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium acetate mixture (30 mmol/ml)
Description: Patients with a magnesium retention test \>25% and randomized to intervention receive magnesium acetate oral mixture (30 mmol/ml) 20 ml x 3/day for a period of three weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-protein diet (2 g/kg/day)
Description: Nutritional counseling and protein supplementation to establish an intake of 2 g protein kg/day during admission and three weeks after discharge.
Study: NCT05885113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIDCAP Developmental Care
Description: The intervention of Individualized Developmental Care (IDC) is designed to minimize the mismatch between the fragile infant brain's expectations and the experiences of stress and pain inherent in the hospital environment. An ICU that provides individualized, developmentally-supportive care includes a soothing environment, supports parents as their child's primary caregiver, providing continual adjustment of caregiving in support of the child's wellbeing by reading the infant's cues and providing interventions to calmness throughout caregiving, capitalizing on the infant's strengths, and providing supports toward healing, growth and learning. NIDCAP is the experimental intervention to be tested in the current study. NIDCAP is the only evidence-based, comprehensive, internationally recognized program of IDC.
Study: NCT05063305

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The probiotic to be used in the study is in capsule form and consists of 12 bacterial strains and 10-billion colony forming unit (CFU). The product consists of the following bacterial strains and species: Bifidobacterium infantis ATCC SD 6720, Bifidobacterium bifidum ATCC SD 6576, Bifidobacterium breve ATCC SD 5206, Bifidobacterium lactis ATCC SD 5220, Bifidobacterium longum ATCC SD 5588, Lactobacillus acidophilus DSM 32754, Lactobacillus casei ATCC SD5213, Lactobacillus paracasei ATCC SD 5275, Lactobacillus plantarum ATCC SD 5209, Lactobacillus reuteri ATCC SD 6689, Lactobacillus rhamnosus ATCC 53103, Lactobacillus salivarius ATCC SD 5208) in combination with the prebiotic, xylooligosacharide (XOS).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The probiotic to be used in the study is in capsule form and consists of 12 bacterial strains and 10-billion colony forming unit (CFU). The product consists of the following bacterial strains and species: Bifidobacterium infantis ATCC SD 6720, Bifidobacterium bifidum ATCC SD 6576, Bifidobacterium breve ATCC SD 5206, Bifidobacterium lactis ATCC SD 5220, Bifidobacterium longum ATCC SD 5588, Lactobacillus acidophilus DSM 32754, Lactobacillus casei ATCC SD5213, Lactobacillus paracasei ATCC SD 5275, Lactobacillus plantarum ATCC SD 5209, Lactobacillus reuteri ATCC SD 6689, Lactobacillus rhamnosus ATCC 53103, Lactobacillus salivarius ATCC SD 5208) in combination with the prebiotic, xylooligosacharide (XOS).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo, that will be indistinguishable in appearance to the probiotic, will be provided to half of all study participants for the length of the trial. It will contain the following ingredients: Microcrystalline cellulose, magnesium stearate, a vegetarian capsule, and silicon dioxide. The probiotic will be manufactured by MeriCal.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo, that will be indistinguishable in appearance to the probiotic, will be provided to half of all study participants for the length of the trial. It will contain the following ingredients: Microcrystalline cellulose, magnesium stearate, a vegetarian capsule, and silicon dioxide. The probiotic will be manufactured by MeriCal.
Study: NCT05259150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health for Hearts United Delivery of Health
Description: The Organization (church) uses best practices to implement Heart Health activities (annual plans, achievements, plans for the year and practices).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health for Hearts United Delivery of Health
Description: The Organization (church) uses best practices to implement Heart Health activities (annual plans, achievements, plans for the year and practices).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health for Hearts United Comparison Group Health Ministry Development
Description: Participants (health leaders) have meetings to develop the health ministry. Research participants (church congregants) do not receive cardiovascular health program.
Study: NCT02410421

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional magnetic resonance imaging used to individualize rTMS protocol using robotic coil positioning

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging used to individualize rTMS protocol using robotic coil positioning

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional magnetic resonance imaging used to individualize rTMS protocol using robotic coil positioning
Study: NCT05828849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation, compensation, and personalization
Description: The study intervention is composed of navigation, compensation, and personalization. Navigation refers to reducing barriers posed by fragmentation of health and social systems. Compensation refers to reimbursement of out-of-pocket expenses to offset dependent care, time costs, and travel expenditures necessary to access care for the different conditions and goals of the intervention. Personalization refers to preventative interventions that are personalized based on individual for potential benefit.
Study: NCT06255821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: One-session of graded in-vivo exposure with a spider. Each task is first modeled by the experimenter. Prior to the exposure, participants receive psychoeducation on anxiety and phobias.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: One-session of graded in-vivo exposure with a spider. Each task is first modeled by the experimenter. Prior to the exposure, participants receive psychoeducation on anxiety and phobias.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: One-session of graded in-vivo exposure with a spider. Each task is first modeled by the experimenter. Prior to the exposure, participants receive psychoeducation on anxiety and phobias.
Study: NCT05696925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Execution of the Action
Description: In the sitting or standing position, depending on the action to be performed, the participant must execute the same action imagined or observed previously.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Execution of the Action
Description: In the sitting or standing position, depending on the action to be performed, the participant must execute the same action imagined or observed previously.
Study: NCT05502146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noradrenaline Bitartrate
Description: An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Subarachnoid block will be performed using Bupivacaine hydrochloride (2.5 mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Noradrenaline Bitartrate
Description: An intravenous bolus of norepinephrine 8 mcg will be administered for management of maternal hypotension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Subarachnoid block will be performed using Bupivacaine hydrochloride (2.5 mL)
Study: NCT03486444

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Phillips Lumify Diagnostic Ultrasound System
Description: portable ultrasound device

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Phillips Lumify Diagnostic Ultrasound System
Description: portable ultrasound device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: surveys assessing perception of ultrasound

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: surveys assessing perception of ultrasound

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: surveys assessing perception of ultrasound
Study: NCT05883917

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot assisted gait training
Description: Gait training using SUBAR® (Cretem, Korea) proceeded by adjusting parameters (gait speed, step length, and degree of knee flexion) according to the patient's leg length and gait function. The parameters were set to the maximum levels tolerated by the patient. The patients underwent 30 min of robot-assisted training using SUBAR® with 30 min of conventional physiotherapy, 5 days a week for 12 weeks.
Study: NCT05402540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STRAIN COUNTER STRAIN GROUP
Description: Strain Counterstrain Technique in combination with conventional physiotherapy (Hot pack, Codmans exercises, active assisted exercises, Pendulum exercises, Finger Ladder Exercise, Maitland mobilization of shoulder joint.~Therapist palpate surrounding and opposing tissues to locate trigger point by using one or two finger pads to monitor fasciculation and MTrP.~Hold the POC (position of comfort) until fasciculation decreases significantly or ceases. Average positions hold time while pressure is 90 s to 3 min.~Release tissue or joint slowly and reassess. Each patient will receive total 6 sessions (3sessions/week) over a period of 2 weeks.~Assessment would be done on baseline and after every three sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACTIVE RELESAE TECHNIQUE GROUP
Description: Active Release Technique in combination with conventional physiotherapy (Hot pack, Codmans exercises, active assisted exercises, Pendulum exercises, Finger Ladder Exercise, Maitland mobilization of shoulder joint.~The targeted muscle will be palpated while the therapist will looks for localized tenderness or trigger points with referred pain elicitation.~With the thumb therapist will relieve the trigger point. In ART the particular muscle is taken from shortened to lengthened position or from lengthened to shortened position.~Duration of treatment will be 8-15 minutes. Each patient will receive total 6 sessions (3sessions/week) over a period of 2 weeks.~Assessment would be done on baseline and after every three sessions.
Study: NCT04629781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel micellar
Description: There will be three dose levels, 1-3, with each level consisting initially of a cohort containing 3 patients. One additional dose level, dose level -1, shall be allowed in the event that dose level 1 is considered too toxic
Study: NCT04668638

Intervention type: OTHER
Group type: OTHER
Intervention: Respiratory rehabilitation
Description: Respiratory rehabilitation includes education, hypoventilation exercises, diaphragmatic breathing exercises, relaxation, retraining, others.

Intervention type: OTHER
Group type: OTHER
Intervention: Respiratory rehabilitation
Description: Respiratory rehabilitation includes education, hypoventilation exercises, diaphragmatic breathing exercises, relaxation, retraining, others.
Study: NCT05502744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy is the standard treatment for acute cholecystitis due to the advantages of small wounds, less use of abdominal drains , less need for antibiotics and analgesics and less postoperative hospital stay time.Laparoscopic cholecystectomy in acute cholecystitis may be performed as soon as begging of the symptoms called emergency or urgent and maybe scheduled in advance after controlling acute attack after 6-8weeks called elective.
Study: NCT05955001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg / Placebo
Description: Patients after Holmium laser Enucleation of Prostate (HoLEP) will receive single daily dose of Tadalafil for 3 months and compared to Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg / Placebo
Description: Patients after Holmium laser Enucleation of Prostate (HoLEP) will receive single daily dose of Tadalafil for 3 months and compared to Placebo
Study: NCT05213884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200 mg, intravenous infusion over 30 minutes (Q3W); 1\~3 cycles of camrelizumab before radiotherapy and camrelizumab are maintained for 16 cycles (1 year) after the end of radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin chemotherapy
Description: cisplatin is given at a dose of 40 mg/m2 via intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy every week for 6 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Description: 70 Gy/ 35 fractions/7 weeks, 5 fractions/week, 1 fraction/day.
Study: NCT04725812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Eculizumab Intravenous Solution
Study: NCT04726748

Intervention type: PROCEDURE
Intervention: Comparisons between the Prostatic urethral lift (PUL) and the TURP/Laser cohorts
Description: Comparison between the PUL and the TURP/Laser cohorts will be performed after 1 year and 3 years of follow-up in a intention-to-treat analysis using:~* a linear regression model when it involves quantitative variables,~* a logistic regression model adjusted on potential confounding when it involves qualitative variables.

Intervention type: PROCEDURE
Intervention: Comparisons between the Prostatic urethral lift (PUL) and the TURP/Laser cohorts
Description: Comparison between the PUL and the TURP/Laser cohorts will be performed after 1 year and 3 years of follow-up in a intention-to-treat analysis using:~* a linear regression model when it involves quantitative variables,~* a logistic regression model adjusted on potential confounding when it involves qualitative variables.

Intervention type: PROCEDURE
Intervention: Comparison between the Prostatic urethral lift (PUL) and the SNDS cohorts
Description: Comparison between the PUL and the SNDS cohorts will be performed after 1 year and 3 years of follow-up in a intention-to-treat analysis using:~* a linear regression model when it involves quantitative variables,~* a logistic regression model adjusted on potential confounding when it involves qualitative variables.

Intervention type: PROCEDURE
Intervention: Comparison between the Prostatic urethral lift (PUL) and the SNDS cohorts
Description: Comparison between the PUL and the SNDS cohorts will be performed after 1 year and 3 years of follow-up in a intention-to-treat analysis using:~* a linear regression model when it involves quantitative variables,~* a logistic regression model adjusted on potential confounding when it involves qualitative variables.
Study: NCT05051267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Pharmacological Methods
Description: All of the applications that increase the effectiveness of drugs when used together with analgesics and provide the elimination of pain by releasing our body's natural morphine and endorphins without the use of analgesics are called non-pharmacological treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Pharmacological Methods
Description: All of the applications that increase the effectiveness of drugs when used together with analgesics and provide the elimination of pain by releasing our body's natural morphine and endorphins without the use of analgesics are called non-pharmacological treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Pharmacological Methods
Description: All of the applications that increase the effectiveness of drugs when used together with analgesics and provide the elimination of pain by releasing our body's natural morphine and endorphins without the use of analgesics are called non-pharmacological treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Pharmacological Methods
Description: All of the applications that increase the effectiveness of drugs when used together with analgesics and provide the elimination of pain by releasing our body's natural morphine and endorphins without the use of analgesics are called non-pharmacological treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Pharmacological Methods
Description: All of the applications that increase the effectiveness of drugs when used together with analgesics and provide the elimination of pain by releasing our body's natural morphine and endorphins without the use of analgesics are called non-pharmacological treatment.
Study: NCT05050266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EBQI
Description: EBQI is a systematic quality improvement method for engaging frontline practices in improvement that introduces best science and evidence in the service of operational goals. EBQI has been tested in several VA implementation trials. Sites randomized to EBQI will meet monthly with the implementation support team (i.e., high-intensity).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: REP
Description: The REP framework consists of 4 phases: pre-conditions, pre-implementation, implementation and maintenance/evolution. REP has a strong evidence-base and application in VHA health services research in promoting uptake of EBPs. Sites randomized to REP will meet quarterly with the implementation support team (i.e., low-intensity).
Study: NCT04777929

Intervention type: OTHER
Intervention: test Phthalates, estrogen and progesterone
Description: test mothers Phthalates in their urine, and test estrogen and progesterone receptor in placental tissue

Intervention type: OTHER
Intervention: test Phthalates, estrogen and progesterone
Description: test mothers Phthalates in their urine, and test estrogen and progesterone receptor in placental tissue
Study: NCT04940013

Intervention type: DRUG
Group type: OTHER
Intervention: Misoprostol
Description: Study participants are given misoprostol alone for menstrual regulation.